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Abstract
Over the last half century, platelet transfusion has been an effective therapy for the prevention and
treatment of bleeding, particularly in patients with hematologic malignancies. Recent randomized
trials have demonstrated that current practices may be suboptimal in a number of ways. The rationale
for parsimony in the use of this powerful therapy includes previously described severe and fatal
adverse outcomes (including refractoriness, hemolysis from ABO-mismatched transfusions, acute
lung injury, and bacterial sepsis), newly described serious potential risks (including thrombosis and
earlier leukemic recurrence), difficulty in maintaining adequate supplies of platelets, the need to place
volunteer donors on cell separators to provide the product, and cost. Recent findings demonstrate
that the platelet count threshold for prophylactic transfusion can be as low as 10,000/µL, and a
therapeutic rather than a prophylactic strategy of transfusion for bleeding manifestations only may be
equally safe for most patients. Another recently completed study suggests that very low doses of
platelet transfusions (the equivalent of half a unit of apheresis platelets or two to three units of whole
blood-derived platelets) are as effective at preventing bleeding as much higher doses. One question
for which there are no randomized trial data is at what threshold prophylactic platelet transfusion
should be given before invasive procedures or major surgery. The typically recommended threshold
of 50,000/µL is based only on expert opinion, and substantial observational data indicate that this
threshold leads to many transfusions that are likely unnecessary and therefore represent risk with
little or no additional benefit.
Introduction and context
Source, dose, benefits, risks, and prophylactic
transfusion triggers
The goal of platelet transfusion is to stop or prevent
bleeding in thrombocytopenic patients or those with
platelet dysfunction [1-3]. Bleeding is a relatively
uncommon cause of death in non-trauma patients
but can be a significant morbid event at worst and, at
best, quite upsetting for patients, families, and
providers. Thus, traditionally, with the view that
platelet transfusion is essentially benign, the impetus
has been to transfuse platelets aggressively to prevent
rather than treat bleeding. There are two types of
platelet products for transfusion. Whole blood plate-
lets, which are derived from four to five whole blood
donations, pooled, leukoreduced, bacterially tested,
and irradiated, used to be the standard transfusion
product but now are less frequently used in the US.
Apheresis platelets derived from donors who spend a
couple of hours on a cell separator have become the
most commonly used product in the US. The usual
doses have been in the range of 3 × 10
11 to 5 × 10
11
platelets per transfusion but one-quarter to one-half of
these doses has been shown to be equivalent in
preventing bleeding in a recent but as yet unpublished
large national randomized trial (Prophylactic Platelet
Dose on Transfusion Outcomes, or PLADO) [4].
Whole blood pooled and apheresis platelets are
considered by most experts to be interchangeable in
terms of efficacy and safety.
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Patients receiving pheresis platelets are likely to have a
higher risk of hemolytic reactions if they are ABO-
mismatched [5-7] and a higher risk of acute lung injury
(transfusion-related acute lung injury) due to having
larger amounts of plasma from a single donor, but carry
a lower risk of infectious disease transmission due to
fewer donor exposures. Earlier studies have demon-
strated that alloimmunization and refractoriness to
transfusion (inability to raise the platelet count with
transfusion) are common in recipients of non-
leukoreduced transfusions [8] and ABO-mismatched
platelet transfusions [9]. Thus, almost everyone agrees
that platelet transfusions should always be leukoreduced
and that every effort should be made to use only ABO-
identical platelets whenever possible.
For patients who have severe or repeated fever, rigors, or
allergic or pulmonary complications with transfusion
(about 1-5% of patients; mostly fever, rigors, and/or
urticaria), saline-washed platelets are available in some
hospitals [10]. These require about 2 hours of additional
preparation time and contain about 20% fewer platelets
than unwashed platelets. One study suggests that clinical
outcomes (survival) are improved with the use of
washed platelets in adult patients with acute leukemia
and that post-transfusion fever, rigors, and urticaria can
be almost completely eliminated [11].
Indications
Traditionally, platelet transfusions in hematology-
oncology have been given prophylactically as serious
bleeding is fortunately uncommon in these patients. The
safe threshold for prophylactic transfusion in a clinically
stable patient who does not have serious bleeding (e.g.,
that requiring red cell transfusion or representing serious
orlife-threateningmorbidity)isconsideredtobeaplatelet
countof10,000/µL[12-14].Thereisreasonableconsensus
that for patients who are bleeding, septic, or hemodyna-
mically unstable, the threshold for transfusion should be
raised to 15,000-20,000/µL. Patients with life-threatening
bleeding in the chest or head are usually transfused at
higher platelet count thresholds (30,000-50,000/µL).
Despite the evidence that a platelet count of more than
10,000/µL is adequate to prevent spontaneous hemor-
rhage and that serious bleeding is quite rare at counts
above 20,000/µL, many interventionalists and surgeons
nonetheless insist on platelet counts of at least 25,000/µL
for multi-lumen catheter insertion and 50,000/µL for
invasive procedures such as major surgery or liver or lung
biopsy. The evidence in support of these practices is nil,
buttraditionalpracticesdonotchangewithoutconvincing
evidence demonstrating that they are unnecessary or even
counterproductive, and these practices may well be both.
An uncommon indication for platelet transfusion is a
platelet dysfunction (due to disease or a commonly
employed drug such as aspirin) that is associated with
serious bleeding or that accompanies the need for major
surgery or another high-risk invasive procedure such as
liver biopsy.
One reason that strategies for platelet transfusion have
been difficult to study and change is that the effectiveness
of platelet transfusion is not easily evaluated. If the
transfusion is therapeutic, then the amount and rate of
bleeding are the only really important measures of
response. Quantitation of these is not easily achieved.
There are no laboratory tests that adequately measure the
efficacy of platelet transfusion, thus clinical evaluation is
the only appropriate approach. In the case of prophy-
lactic platelet transfusions, the situation is even more
difficult. The increase in platelet count is the only
available response measure other than the absence of
bleeding. The general goal has been to achieve a platelet
count above 20,000/µL, but the post-transfusion platelet
count is usually not measured except in hematology-
oncology patients and, in any case, platelet count
correlates very poorly with bleeding. Typically, platelet
counts are performed each morning and if the count is
below 10,000/µL, a platelet transfusion is given. In
patients with bleeding or requiring invasive procedures,
post-transfusion platelet counts can be performed at any
time after the transfusion, from a few minutes to a few
hours. Because increments are often transient in acutely
ill patients, the transfusion should be performed just
prior to any invasive procedure, not the day before or
several hours before. A common practice, albeit one
based on common sense rather than data, is to infuse
platelets during the procedure to ensure that additional
platelets are present during the time of maximal
challenge to hemostasis.
Platelet transfusion refractoriness
If refractoriness to platelet transfusion (poor post-
transfusion platelet count increments) is suspected, this
is evaluated primarily by immediate post-transfusion
count increments (approximately 10-60 minutes after
completion of the transfusion). HLA antibody-mediated
immune refractoriness is further differentiated from
other causes such as sepsis, hypersplenism, and drug-
related causes by measurement of anti-platelet/anti-HLA
antibodies and failure to raise the platelet count post-
transfusion. In other causes, there is often a short-lived (a
few hours) rise in count but poor platelet survival post-
transfusion. The most common cause of severe refrac-
toriness is allosensitization, the formation of IgG
antibodies to HLA-A,B (class I major histocompatibility
complex) antigens in the transfusion recipient due to
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munization to HLA class I and II or granulocyte antigens
(i.e., antibody in the platelet product) can be an etiology
for transfusion-related acute lung injury in the recipient.
Recipient alloimmunization to HLA class I in previous
non-sensitized patients is almost entirely prevented by
using leukoreduced red cells from which the platelets
and white cells have been removed by filtration and
leukoreduced platelets from which the white cells have
been removed [8]. Universal leukoreduction is standard
procedure at almost all European hospitals. Unfortu-
nately, not all hospitals in the US practice universal
leukoreduction of blood components, thus patients may
come to referral centers with recent prior transfusion
sensitization. Women, particularly those with multiple
pregnancies, are more likely to experience this complica-
tion than men are. Unfortunately, once refractoriness has
developed, it portends a poor overall prognosis [15].
In the refractory patient, anti-HLA class I antibody tests
using panel reactivity that employs a cytotoxicity method
are often used. An enzyme-linked immunosorbent assay
or immunofluorescent assay that detects anti-platelet-
specific antibodies (very rare) and HLA class I antibodies
is also used in some instances. If specificities can be
determined, selecting platelet donors who lack the class I
HLA antigens to which the recipient has antibody is the
simplest and fastest approach to dealing with immune
refractoriness. Two other strategies have some success:
HLA-A,B-matched platelets and crossmatched platelets.
Both strategies have a good but not great success rate
of about 50-75% if a grade A or B HLA match
or crossmatched platelet apheresis unit is available.
A grade A or B HLA match is when the donor platelets
carry no HLA-A,B antigens that are not identical with or
serologically cross-reactive with those of the recipient.
Sometimes, a family member, particularly an HLA-
matched sibling who served as the donor for a stem
cell transplant, can be the best donor as they tend to be
closely matched. Many cases of clinical refractoriness
currently are due to drug-related anti-platelet antibodies,
with common offending drugs being vancomycin,
amphotericin, and other anti-microbials (rarely quini-
dine or other drugs). Tests for drug-related antibodies are
not routinely available, and the primary approach is
discontinuing the drug and observing whether transfu-
sion responsiveness returns within a few days to a week
of continuing platelet transfusion.
Recent advances
Recent data suggest the efficacy and safety of transfusing
fewer and lower doses of platelet transfusions. The
clearest indication for platelet transfusion is the pre-
sence of serious bleeding in the setting of severe
thrombocytopenia or platelet dysfunction. A strategy of
transfusing only those patients with evidence of bleeding
is called a therapeutic as opposed to a prophylactic
strategy. This was supported by a recent randomized
trial, and a larger trial is currently under way in the UK
[16]. The evidence is that this strategy leads to fewer
transfusions and no greater incidence of serious bleeding
than a prophylactic strategy. There is obviously more
minor bleeding (petechia, purpura, mild epistaxis, and
so on).
Current opinion is moving toward a therapeutic rather
than a prophylactic strategy as practitioners become
more comfortable in foregoing transfusions in asympto-
matic thrombocytopenic patients with ever lower plate-
let counts. The potential advantage is that platelet
transfusion is far from benign, being associated in recent
studies with multi-organ failure [17], acute lung injury
[18], bacterial sepsis [19,20], and even earlier recurrence
of leukemia [21]. Platelets are clearly an important
component of the innate immune system, perhaps
explaining their postulated pro-inflammatory [22] and
pro-thrombotic effects after storage and transfusion [23].
Preliminary studies raise the possibility that ABO-
mismatched platelet and plasma transfusions predispose
the patient to bleeding and mortality [24]. Recent reports
suggest that platelet transfusions are immunomodula-
tory, pro-inflammatory, and pro-thrombotic [21,25-28].
With increasing evidence of previously undetected
serious and even life-threatening effects of platelet
transfusion, an enthusiastically prophylactic approach
to transfusion is less and less attractive and indeed was
never evidence-based in origin.
Implications for clinical practice
Prophylactic platelet transfusions need not be given for
counts above 10,000/µL or prior to many invasive
procedures for counts above 25,000/µL. Therapeutic
platelet transfusions for bleeding are usually effective
if the count can be raised above 20,000-30,000/µL,
although many experts continue to advocate a threshold
of at least 50,000/µL for major surgery and even at least
100,000/µL for some surgeries. There are no data
supporting these numbers but this is the standard of
practice and what is found in textbooks. The Society for
Interventional Radiology specifies 25,000/µL platelets
as the transfusion threshold for tunneled catheters but
some physicians request even higher counts (unpub-
lished Annual Meeting syllabi). Liver biopsy and other
major procedures require thresholds of 50,000/µL but
there is little or no evidence to suggest that this is optimal
practice. Achieving these thresholds in acutely ill patients
is often difficult and sometimes impossible.
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count is still suboptimal, determine whether the
radiologist, surgeon, or anesthesiologist will accept
platelets transfusing during the procedure as an alter-
native to multiple boluses of platelets in a vain attempt
to achieve an arbitrary number. There are a number of
cases in our institutions in which infusion of three to
seven doses of platelets has been associated with multi-
organ failure after surgery, and there are similar reports
in the literature. Platelet transfusions are likely pro-
thrombotic and pro-inflammatory, and transfused plate-
lets are highly activated [21]. There are very few or no
situations, inour view,in whichasecond or third platelet
transfusion will accomplish what a single platelet
transfusion cannot. Platelet transfusion should not be
considered benign and should be withheld unless there
are compelling clinical indications, and these usually
involve current serious bleeding accompanied by throm-
bocytopenia below 50,000/µL or platelet dysfunction.
Serious bleeding is almost never explained primarily by
thrombocytopenia with a platelet count that is between
50,000 and 100,000/µL in our clinical experience.
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